FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aspire Biopharma Holdings, Inc. As filed with the Securities and Exchange Commission on December 3, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Exact name of registrant as specified in its charter) (State or jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2834 33-3467744 (I.R.S. Employer Identification No.) 23150 Fashion Dri ...

Group 1: Company Performance - Aspire Biopharma Holdings, Inc. saw a stock price increase of 91.71%, reaching a high of $0.43, attributed to advancements in its drug pipeline and plans for a new drug application by 2025 [2][6] - Hepion Pharmaceuticals, Inc. experienced a 73.91% rise in stock price to $0.09, likely due to the completion of its application to the OTCQB market and developments in diagnostic tests for various conditions [3][6] - Mountain Lake Acquisition Corp. had a significant stock price increase of 284.42%, possibly due to anticipation of a major announcement regarding business combination plans [4][6] - RF Acquisition Corp II Right saw a 157.5% rise, driven by optimism surrounding potential mergers or acquisitions in high-growth sectors like artificial intelligence and biotechnology [4][6] Group 2: Market Dynamics - The market is currently dynamic, with notable interest in companies involved in mergers, acquisitions, and advancements in drug therapies and diagnostics [5][6] - Investors are closely monitoring these companies for insights into their operational success and market potential [5]